Cartesian Therapeutics Inc
RNAC
Market Cap$485.65M
Close$
$-8.19
130% downside
Current Fair Value
130% downsideOvervalued by 130% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $485.65 Million |
|---|---|
| Enterprise Value | $392.69 Million |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-64.73 |
| Beta | 0.0 |
| Outstanding Shares | 17,796,053 |
| Avg 30 Day Volume | 92,582 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -1.91 |
|---|---|
| PEG | -1.17 |
| Price to Sales | 27.29 |
| Price to Book Ratio | -3.9 |
| Enterprise Value to Revenue | 15.16 |
| Enterprise Value to EBIT | -4.83 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | -0.09 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Cartesian Therapeutics Inc
81 employees
CEO: Carsten Brunn selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vac...